Corona Remedies Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Corona Remedies Ltd is ₹ 1580 as of 19 Feb 10:41 . The P/E Ratio of Corona Remedies Ltd is 0 as of March 2023 .The P/E Ratio of Remus Pharmaceuticals Ltd is 0 as of March 2023 . The Market Cap of Corona Remedies Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 0 crore as of March 2023 . The revenue of Corona Remedies Ltd for the Dec '25 is ₹ 344.68 crore as compare to the Sep '25 revenue of ₹ 363.57 crore. This represent the decline of -5.2% The revenue of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Corona Remedies Ltd for the Dec '25 is ₹ 66.32 crore as compare to the Sep '25 ebitda of ₹ 80.91 crore. This represent the decline of -18.03% The ebitda of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 41.27 crore over 7 quarters. This represents a CAGR of 20.11% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Corona Remedies Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Corona Remedies Ltd or Remus Pharmaceuticals Ltd?

Market cap of Corona Remedies Ltd is 10,550 Cr while Market cap of Remus Pharmaceuticals Ltd is 807 Cr

What are the key factors driving the stock performance of Corona Remedies Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Corona Remedies Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Corona Remedies Ltd and Remus Pharmaceuticals Ltd?

As of May 4, 2026, the Corona Remedies Ltd stock price is INR ₹1725.0. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹685.3.

How do dividend payouts of Corona Remedies Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Corona Remedies Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.